Japan Tobacco Inc.

Satoru Noji

Hiroshi Yamanaka

Takahiro Oka

Yoko Matsumoto

Toshihiro Sato

Izuru Ando

Ryo Mizojiri

Yasushi Niwa

Kenta Aoki

Masafumi Inoue

Makoto Shiozaki

Tomoya Miura

Kiyotaka Shinoda

Shintaro Hirashima

Kazutaka Ikegashira

Katsuya Maeda

Yoshinori Hara

Kazunori Kurihara

Noriaki Shimoyama

Yukihiro Nomura

Yoshitoshi Kodama

Katsuaki Imamura

Hideo Takagi

Yuichi Naka

Akimi Hori

Goro Ito

Yukihiro Kamiya

Ryuhei Okura

Yasunori Hase

Akihito Fujiwara

Masaru Tanaka

The present invention relates to crystalline forms of the Janus kinase (JAK) inhibitor 3-((3S,4R)-3-methyl-6-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A), as well as, compositions thereof, methods of their preparation, methods of use thereof and methods of quantitation.

Crystalline forms of a Janus kinase inhibitor

A compound of the following general formula [I]: wherein each symbol has the same meaning as defined herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical use of the same in treating organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic disease and chronic myeloproliferative disease.

Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof

The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor

The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X, X, X, Z, Y, Yrepresent a carbon atom or a nitrogen atom, R, R, R, Rrepresent a hydrogen atom, an alkyl group, etc., and Rrepresents a hydrogen atom, a halogen atom, a nitro group, a cyano group, &#x2014;CH(R)(R)&#x2014;O&#x2014;R, &#x2014;C(&#x2550;O)&#x2014;R, a 5- or 6-membered saturated heterocyclic group, an aromatic heterocyclic group, &#x2014;N(R)(R), etc. The aminopyridine compound of the present invention has not only high Syk inhibitory activity but also properties to selectively inhibit Syk. 

Aminopyridine compounds having Syk inhibitory activity

The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Thienopyrrole compound and use thereof as HCV polymerase inhibitor

Growing community of inventors

Takatsuki, Japan

Satoru Noji